常见驱虫药 mebendazole 联合 gefitinib 在小鼠中恢复耐药肺癌对靶向治疗的敏感性
Common deworming drug helps restore lung cancer's sensitivity to targeted therapy in mice
驱虫药 mebendazole(MBZ)联合 gefitinib 在 gefitinib 耐药的非小细胞肺癌细胞和小鼠模型中恢复了对靶向治疗的敏感性,结果发表于 PLOS One。
A form of lung cancer, which is found in about 10%–15% of Western patients and 40%–50% of Asian patients, is driven by a mutation in the epidermal growth factor receptor (EGFR) gene. Gefitinib is a go-to drug that shuts down this protein's signals. However, over time, cancer cells develop resistance to the drug and keep dividing even while treatment is underway, rendering gefitinib powerless. A recent study published in PLOS One has found a way out of this resistance trap.
Rather than developing an entirely new drug to resensitize drug-resistant lung cancer cells and significantly slow tumor growth, researchers turned to an existing deworming drug, mebendazole (MBZ), pairing it with gefitinib. The two drugs attacked cancer in different ways. Gefitinib targeted the tumor's growth signaling pathway, while mebendazole disrupted microtubules, the internal cellular scaffolding cancer cells rely on to divide and transport proteins.
With gefitinib alone, the survival rate of resistant lung cancer cells was 92.7%, and with MBZ alone, it was 80%. However, combining a low dose of MBZ with gefitinib dropped cell survival to 37.7%.
Becoming resistant to drugs
Lung cancer is a growing public health crisis, with the numbers of people who get it and die from it continuing to rise each year. It is the second most common cancer and the main cause of cancer deaths worldwide. In 2020 alone, there were about 2.2 million new cases and 1.8 million deaths, making up 15% of all new cancer cases and a quarter of all cancer-related deaths.
Around 85% of lung cancer cases are non-small cell lung cancer (NSCLC), whose five-year survival rate, even with timely, targeted treatment, is around 6%. An issue compounding the low rate of treatment success is the cancer's ability to resist the drugs designed to kill the rogue cells.
Cancer cells divide so fast that copying their DNA is a constant struggle, a pressure known as replication stress. Earlier studies suggested that resistant cells survive by building a stress-buffering system, which repairs DNA quickly and keeps the copying process steady. If researchers can break down this stress-buffering system, the cells may buckle under their own stress and die.
An earlier study by the same authors also tried the gefitinib and mebendazole combo, but on cell lines like A549, which don't actually rely on EGFR to survive. So those results showed only general cell toxicity, not proof that mebendazole can reverse true, targeted EGFR drug resistance.
So, in this study, they used HCC827 GR5 cells, a human non-small cell lung cancer line that carries an active EGFR mutation but has developed acquired resistance to gefitinib.
Cancer-killing drug duo
Researchers injected 1 million drug-resistant HCC827 GR5 lung cancer cells, suspended in Matrigel, under the skin of 80 female BALB/c mice. Once the tumors reached 80–120 mm³, researchers randomly divided the mice into treatment groups: MBZ at low (10 mg/kg/day) or high (30 mg/kg/day) doses, alongside gefitinib (50 mg/kg/day). To see whether the treatment could keep tumors in check over the long term, researchers compared four groups: a control, MBZ alone, gefitinib alone and a combination of both drugs.
Adding a low dose of mebendazole (0.1 µM) to gefitinib (1 µM) achieved a level of cell killing similar to a fivefold higher dose of single-agent mebendazole. The combination also caused the most single-strand DNA damage of any treatment, increased double-strand breaks in the lung cancer cells and altered stress signaling. By blocking growth signals and disrupting the cell's structural scaffolding through the dual action of the drugs, the combination collapsed the cells' stress-buffering systems.
-
Quantitative analysis of single-strand DNA damage by comet assay. Credit: PLOS One (2026). DOI: 10.1371/journal.pone.0360164 -
Quantitative analysis of double-strand DNA damage by comet assay. Credit: PLOS One (2026). DOI: 10.1371/journal.pone.0360164
Over 40 days, tumors in untreated mice grew 10.58 times their original size, while those in mice receiving the drug combination grew just 4.55 times. The treatment also stretched the median time it took for tumors to double from 6.2 days in untreated mice to 25 days in treated mice.
The results show that a familiar deworming drug may have an unexpected role in treating drug-resistant lung cancer. Lung cancer cells adapt their way around treatment, but pairing the antiparasitic drug mebendazole with gefitinib could disarm those defenses. Before it can reach the clinic, further trials must test its safety and efficacy and establish a regimen suitable for clinical use.
Written for you by our author Sanjukta Mondal, edited by Gaby Clark, and fact-checked and reviewed by Robert Egan—this article is the result of careful human work. We rely on readers like you to keep independent science journalism alive. If this reporting matters to you, please consider a donation (especially monthly). You'll get an ad-free account as a thank-you.
Publication details
Mohamed El-Tanani et al., Dual targeting of EGFR signaling and microtubule dynamics enhances replication-associated cellular stress and suppresses tumor growth in gefitinib-resistant non-small cell lung cancer, PLOS One (2026). DOI: 10.1371/journal.pone.0360164
Journal information: PLoS ONE
Who's behind this story?
Sanjukta Mondal
Master's in Chemistry. Freelance science journalist and communicator. Published in Chemistry World, BioSpace, and The Hindu. Full profile →
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
© 2026 Science X Network
Citation: Common deworming drug helps restore lung cancer's sensitivity to targeted therapy in mice (2026, October 14) retrieved 14 October 2026 from https://medicalxpress.com/news/2026-10-common-deworming-drug-lung-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com